Age Related CataractsEMONCT05822089
Intraindividual Comparison of EMO IOLs
A study testing phacoemulsification and intraocular lens implantation in people with Age Related Cataracts, run by Medical University of Vienna at 1 site in Austria.
Trial summary
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Read more about this study
- Who is it for?
- Ages 50 to 100 years
- Conditions the study is for
- Age Related Cataracts
- What is being tested?
- phacoemulsification and intraocular lens implantation
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 461 participants
- Where
- 1 siteAustria
- Study dates
- 13 Dec 2021to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation
- Age 50 to 100
- Visual potential in both eyes of 20/25 or better as determined by investigators estimation
- Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Irregular Astigmatism (Acrysof IQ Vivity IOL, IC-8 Apthera IOL)
- postoperativ binocular best corrected distance visual acuity (BCVA) ≥ 1.0 decimal (Arm ten (X))
- Standard cataract surgery with bilateral implantation of a monofocal IOL (Vivinex XC1 or Vivinex XY1) (Arm ten (X))
Who cannot join
- Preceding intraocular surgery or ocular trauma
- Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma)
- Pupil diameter < 2.0 mm (photopic)
- Laser treatment
- Uncontrolled systemic or ocular disease
- Pregnancy/Nursing
- childbearing ability
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
Medical University of Vienna
Vienna
Christina Leydolt, MD, +4314040079480, christina.leydolt@meduniwien.ac.at
About this study
Official title: Comparison of Visual Outcomes of Enhanced Monofocal Intraocular Lenses
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved investigational plan.
- Conditions
- Age Related Cataracts
- Being tested
- phacoemulsification and intraocular lens implantation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (EnVista) vs. an enhanced monofocal IOL (EnVista Aspire)
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced depth of focus IOL (PureSee) in both eyes
phacoemulsification and intraocular lens implantationProcedure or surgery
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) in both eyes or a monofocal IOL (Vivinex XC1) in both eyes
| Study group | Role | What they receive |
|---|---|---|
| Monofocal IOL I vs. enhanced monofocal IOL I | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00) Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Monofocal IOL II vs. enhanced monofocal IOL I | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive a monofocal IOL (Sensar 1AAB00) vs. an enhanced monofocal IOL (ICB00) Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Monofocal IOL III vs. enhanced monofocal IOL II | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm three (III) participants will receive a monofocal IOL (Vivinex XY1)vs. an enhanced monofocal IOL (Vivinex Impress). Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Enhanced monofocal IOL II vs. enhanced monofocal IOL II | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm four (IV) participants will receive an enhanced monofocal IOL (Vivinex Impress) bilateral with a monovision target Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Monofocal IOL IV vs. enhanced monofocal IOL III | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm five (V) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart) Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Extended depth of focus IOL IV in eyes with low to moderate irregular astigmatism | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm six (VI) participants will receive an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed. Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Extended Depth of Focus IOL in eyes with irregular astigmatism | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm seven (VII) participants will receive an extended depth of focus IOL (IC-8 Apthera IOL) in one eye if irregular astigmatism is observed. Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Monofocal IOL IV vs. enhanced monofocal IOL IV | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm eight (VIII) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (EnVista Aspire) Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Enhanced depth of focus IOL I vs. Enhanced depth of focus IOL I | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm nine (IX) participants will receive an enhanced depth of focus IOL (PureSee) bilateral with a monovision target. Receives: Procedure: phacoemulsification and intraocular lens implantation |
| Monofocal IOL VI and monofocal IOL III | Experimental | The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm ten (X) participants will receive a monofocal IOL (Vivinex XC1) bilateral or a monofocal IOL (Vivinex XY1) bilateral. Receives: Procedure: phacoemulsification and intraocular lens implantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distant corrected intermediate visual acuity
Primary outcome measure will be monocular distant corrected intermediate visual acuity (DCIVA) of each intraocular lens implanted. DCIVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.
Measured: 2-6 months
Best-corrected distance visual acuity (BCDVA) - Acrysof IQ Vivity IOL, IC-8 Apthera IOL
Primary outcome measure will be monocular best-corrected distance visual acuity (BCDVA) of each intraocular lens implanted in eyes with irregular astigmatism. BCDVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.
Measured: 3-5 months
Contrast sensitivity and reading ability - Vivinex XC1 and Vivinex XY1
Primary outcome measures for arm ten (X) will be the distance corrected contrast sensitivity and near corrected reading ability and reading speed. Contrast sensitivity will be assessed under standard photopic (85cd/m2) and mesopic (3cd/m2) conditions
Measured: 2-6 months and 1-5 years
Secondary outcomes (1)
Contrast sensitivity and reading ability
Secondary outcome measures will be the distance corrected contrast sensitivity and near corrected reading ability and reading speed. Contrast sensitivity will be assessed under standard photopic (85cd/m2) and mesopic (3cd/m2) conditions.
Measured: 2-6 months and 1-5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2023
- Study start13 Dec 2021
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age Related CataractsStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Intra-individual comparison of 7 groups receiving predefined monofocal and enhanced monofocal intraocular lenses (EMO IOLs). Investigated IOLs will be implanted subsequently according to the study protocol with one IOL type in the dominant eye and the other IOL type in the non- dominant eye.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 461 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christina Leydolt, Medical University of Vienna
- Investigators
- Christina Leydolt, MD, Principal investigator, Medical University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05822089
- Sponsor's protocol ID
- 1631/2021
- Acronym
- EMO
- Status last verified
- Nov 2025
- First submitted
- 7 Apr 2023
- Last updated
- 5 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Visual Outcomes of Enhanced Monofocal Intraocular Lenses
- ClinicalTrials.gov ID
- NCT05822089
- Acronym / sponsor ID
- EMO / 1631/2021
- Conditions
- Age Related Cataracts
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 461 participants (estimated)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Study start
- 13 Dec 2021 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 20 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved investigational plan.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 10
- Model description
- Intra-individual comparison of 7 groups receiving predefined monofocal and enhanced monofocal intraocular lenses (EMO IOLs). Investigated IOLs will be implanted subsequently according to the study protocol with one IOL type in the dominant eye and the other IOL type in the non- dominant eye.
| Arm | Type | Receives |
|---|---|---|
| Monofocal IOL I vs. enhanced monofocal IOL I | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00) |
| Monofocal IOL II vs. enhanced monofocal IOL I | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive a monofocal IOL (Sensar 1AAB00) vs. an enhanced monofocal IOL (ICB00) |
| Monofocal IOL III vs. enhanced monofocal IOL II | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm three (III) participants will receive a monofocal IOL (Vivinex XY1)vs. an enhanced monofocal IOL (Vivinex Impress). |
| Enhanced monofocal IOL II vs. enhanced monofocal IOL II | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm four (IV) participants will receive an enhanced monofocal IOL (Vivinex Impress) bilateral with a monovision target |
| Monofocal IOL IV vs. enhanced monofocal IOL III | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm five (V) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart) |
| Extended depth of focus IOL IV in eyes with low to moderate irregular astigmatism | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm six (VI) participants will receive an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed. |
| Extended Depth of Focus IOL in eyes with irregular astigmatism | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm seven (VII) participants will receive an extended depth of focus IOL (IC-8 Apthera IOL) in one eye if irregular astigmatism is observed. |
| Monofocal IOL IV vs. enhanced monofocal IOL IV | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm eight (VIII) participants will receive an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (EnVista Aspire) |
| Enhanced depth of focus IOL I vs. Enhanced depth of focus IOL I | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm nine (IX) participants will receive an enhanced depth of focus IOL (PureSee) bilateral with a monovision target. |
| Monofocal IOL VI and monofocal IOL III | Experimental | Procedure: phacoemulsification and intraocular lens implantationThe investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm ten (X) participants will receive a monofocal IOL (Vivinex XC1) bilateral or a monofocal IOL (Vivinex XY1) bilateral. |
Who may qualify
- Ages
- 50 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Bilateral age-related cataract planned for phacoemulsification extraction and posterior IOL implantation
- Age 50 to 100
- Visual potential in both eyes of 20/25 or better as determined by investigators estimation
- Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Irregular Astigmatism (Acrysof IQ Vivity IOL, IC-8 Apthera IOL)
Key exclusion criteria (7 listed)
- Preceding intraocular surgery or ocular trauma
- Relevant other ophthalmic diseases that particularly effects the zonular apparatus (such as severe pseudoexfoliation syndrome, preceding cryocoagulation, trauma)
- Pupil diameter < 2.0 mm (photopic)
- Laser treatment
- Uncontrolled systemic or ocular disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00) | Procedure or surgery | Monofocal IOL I vs. enhanced monofocal IOL I |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00) | Procedure or surgery | Monofocal IOL II vs. enhanced monofocal IOL I |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress) | Procedure or surgery | Monofocal IOL III vs. enhanced monofocal IOL II |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes | Procedure or surgery | Enhanced monofocal IOL II vs. enhanced monofocal IOL II |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart) | Procedure or surgery | Monofocal IOL IV vs. enhanced monofocal IOL III |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed | Procedure or surgery | Extended depth of focus IOL IV in eyes with low to moderate irregular astigmatism |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed | Procedure or surgery | Extended Depth of Focus IOL in eyes with irregular astigmatism |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (EnVista) vs. an enhanced monofocal IOL (EnVista Aspire) | Procedure or surgery | Monofocal IOL IV vs. enhanced monofocal IOL IV |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced depth of focus IOL (PureSee) in both eyes | Procedure or surgery | Enhanced depth of focus IOL I vs. Enhanced depth of focus IOL I |
| phacoemulsification and intraocular lens implantationbilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) in both eyes or a monofocal IOL (Vivinex XC1) in both eyes | Procedure or surgery | Monofocal IOL VI and monofocal IOL III |
Primary outcome
Distant corrected intermediate visual acuity
Time frame: 2-6 months
Primary outcome measure will be monocular distant corrected intermediate visual acuity (DCIVA) of each intraocular lens implanted. DCIVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.
Best-corrected distance visual acuity (BCDVA) - Acrysof IQ Vivity IOL, IC-8 Apthera IOL
Time frame: 3-5 months
Primary outcome measure will be monocular best-corrected distance visual acuity (BCDVA) of each intraocular lens implanted in eyes with irregular astigmatism. BCDVA will be assessed using standardized early treatment diabetic retinopathy study (EDTRS) charts on a logarithm of the minimum angle of resolution (logMAR) scale.
Contrast sensitivity and reading ability - Vivinex XC1 and Vivinex XY1
Time frame: 2-6 months and 1-5 years
Primary outcome measures for arm ten (X) will be the distance corrected contrast sensitivity and near corrected reading ability and reading speed. Contrast sensitivity will be assessed under standard photopic (85cd/m2) and mesopic (3cd/m2) conditions
1 secondary outcome
Contrast sensitivity and reading ability
Time frame: 2-6 months and 1-5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Age Related Cataracts
Active, not recruitingObservational study
Age-Related Eye Disease Study (AREDS) Follow-Up
Age-Related Macular Degeneration, Cataract
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
Recruiting
Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice
Vision Impairment and Blindness, Glaucoma
Active, not recruitingPhase 2
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract
Age Related Cataracts
Active, not recruitingObservational study
Multicenter Study on the Use of Intraoperative OCT in the Diagnosis and Management of Lens Diseases
Lens Diseases, Cataract
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Christina Leydolt, MD principal investigator
Medical University of Vienna
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing phacoemulsification and intraocular lens implantation in people with Age Related Cataracts, run by Medical University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christina Leydolt, MD (+43 (01) 40 400 79480, christina.leydolt@meduniwien.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distant corrected intermediate visual acuity (time frame: 2-6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2025.